| Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity J Van Ryn, J Stangier, S Haertter, KH Liesenfeld, W Wienen, M Feuring, ... Thrombosis and haemostasis 103 (06), 1116-1127, 2010 | 1861 | 2010 |
| Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients AM Gallagher, E Setakis, JM Plumb, A Clemens, TP van Staa Thrombosis and haemostasis 106 (11), 968-977, 2011 | 494 | 2011 |
| Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor J Stangier, A Clemens Clinical and applied thrombosis/hemostasis 15 (1_suppl), 9S-16S, 2009 | 431 | 2009 |
| Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control CL Morgan, P McEwan, A Tukiendorf, PA Robinson, A Clemens, ... Thrombosis research 124 (1), 37-41, 2009 | 386 | 2009 |
| Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork … P Kirchhof, GYH Lip, IC Van Gelder, J Bax, E Hylek, S Kaab, U Schotten, ... Europace 14 (1), 8-27, 2012 | 339 | 2012 |
| Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice MV Huisman, GYH Lip, HC Diener, M Brueckmann, J van Ryn, A Clemens Thrombosis and haemostasis 107 (05), 838-847, 2012 | 317 | 2012 |
| Effective elimination of dabigatran by haemodialysis D Khadzhynov, F Wagner, S Formella, E Wiegert, V Moschetti, T Slowinski, ... Thrombosis and haemostasis 109 (04), 596-605, 2013 | 254 | 2013 |
| Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin WG Eisert, N Hauel, J Stangier, W Wienen, A Clemens, J van Ryn Arteriosclerosis, thrombosis, and vascular biology 30 (10), 1885-1889, 2010 | 238 | 2010 |
| Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment FA Klok, V Hösel, A Clemens, WD Yollo, C Tilke, S Schulman, M Lankeit, ... European Respiratory Journal 48 (5), 1369-1376, 2016 | 215 | 2016 |
| Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference P Kirchhof, G Breithardt, E Aliot, S Al Khatib, S Apostolakis, A Auricchio, ... Europace 15 (11), 1540-1556, 2013 | 209 | 2013 |
| Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care … M Yoon, PS Yang, E Jang, HT Yu, TH Kim, JS Uhm, JY Kim, JH Sung, ... Thrombosis and haemostasis 119 (10), 1695-1703, 2019 | 203 | 2019 |
| Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) MD Ezekowitz, R Nagarakanti, H Noack, M Brueckmann, C Litherland, ... Circulation 134 (8), 589-598, 2016 | 199 | 2016 |
| Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral … MV Huisman, GYH Lip, HC Diener, SJ Dubner, JL Halperin, CS Ma, ... American heart journal 167 (3), 329-334, 2014 | 182 | 2014 |
| Stroke prevention in atrial fibrillation—an Asian stroke perspective HF Tse, YJ Wang, MA Ai-Abdullah, AB Pizarro-Borromeo, CE Chiang, ... Heart rhythm 10 (7), 1082-1088, 2013 | 175 | 2013 |
| Prognostic value of codon 918 (ATG→ACG) RET proto‐oncogene mutations in sporadic medullary thyroid carcinoma T Schilling, J Bürck, HP Sinn, A Clemens, HF Otto, W Höppner, C Herfarth, ... International journal of cancer 95 (1), 62-66, 2001 | 167 | 2001 |
| Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials RJ Friedman, OE Dahl, N Rosencher, JA Caprini, AA Kurth, CW Francis, ... Thrombosis research 126 (3), 175-182, 2010 | 162 | 2010 |
| Patient outcomes using the European label for dabigatran GYH Lip, A Clemens, H Noack, J Ferreira, SJ Connolly, S Yusuf Thrombosis and haemostasis 112 (05), 933-942, 2014 | 153 | 2014 |
| Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate NS Roskell, GYH Lip, H Noack, A Clemens, JM Plumb Thrombosis and haemostasis 104 (12), 1106-1115, 2010 | 153 | 2010 |
| Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution J Lüttges, A Reinecke-Lüthge, B Möllmann, MAOH Menke, A Clemens, ... Virchows Archiv 435, 461-468, 1999 | 144 | 1999 |
| Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation F Skjøth, TB Larsen, LH Rasmussen, GYH Lip Thrombosis and haemostasis 112 (05), 981-988, 2014 | 126 | 2014 |
